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Abstract: Background: Although rates of cardiovascular disease complicating type 2 diabetes are
declining, equivalent data for renal replacement therapy (RRT) are conflicting. The aim of this study
was to characterize temporal changes in RRT incidence rates (IRs) in Australians with or without
type 2 diabetes. Methods: Participants with type 2 diabetes from the Fremantle Diabetes Study
Phases I (FDS1; n = 1291 recruited 1993–1996) and II (FDS2; n = 1509 recruited 2008–2011) were age-,
sex- and postcode-matched 1:4 to people without diabetes and followed for first hospitalization
for/with RRT. Five-year IRs, IR ratios (IRRs) for those with versus without diabetes in FDS1 and
FDS2, and IR differences (IRDs), were calculated. Results: The 13,995 participants had a mean age
of 64.8 years and 50.4% were males. For the type 2 diabetes cohorts, the 5-year RRT IR was nearly
threefold higher in FDS2 versus FDS1 (IRR (95% CI): 2.85 (1.01–9.87)). Sixteen more participants
with type 2 diabetes/10,000 person-years received RRT in FDS2 than FDS1 compared with an IRD of
2/10,000 person-years in those without diabetes. Type 2 diabetes increased RRT risk at least 5-fold.
This increased risk was greater in Aboriginal participants who were relatively young when RRT was
initiated and more prone to rapid progression to RRT. Multivariable analysis using the combined FDS
type 2 diabetes cohorts confirmed albuminuria as a strong independent RRT risk factor. Conclusions:
The incidence of RRT is increasing substantially in Australians with type 2 diabetes, especially in
Aboriginals who progress to RRT more rapidly at a younger age than non-Aboriginals.
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1. Introduction
Several longitudinal studies from North America, Europe, Asia and Australia have
demonstrated that there has been a decline in chronic macrovascular complications of
diabetes over the past few decades [1–4] as well as in all-cause and cardiovascular disease
(CVD) death [5,6], reflecting improving CVD risk factor management [7–9]. Although these
encouraging trends may be stabilizing and even reversing based on even more recent US
data [10,11], there is still the possibility that other complications such as chronic kidney
disease (CKD) may become more prominent as longevity increases [12].
Although there is some evidence of CKD leading to end-stage kidney disease (ESKD)
and the need for renal replacement therapy (RRT) has been declining in parallel with CVD
in type 2 diabetes in some countries, the trend has not been as marked as that for major CVD
outcomes such as myocardial infarction (MI) and stroke [2,3]. In addition, recent national
data relating to temporal trends in CKD complicating type 2 diabetes are inconsistent,
with some studies showing a reduction [3,13] and others an increase [12,14–17] in CKD
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hospitalizations and progression to RRT. The use of administrative data in these studies
has well-recognized limitations, including incomplete ascertainment of diabetes and its
type, misclassification of endpoints, inconsistent follow-up and missing patient-level data,
and lack of detailed data relating to risk factors and clinical management. In addition, the
decision to start RRT may depend on local eligibility criteria, as well as the availability
of specialist renal services, dialysis facilities, and donor kidneys. These factors, which
may disadvantage people with diabetes and associated comorbidities such as obesity and
CVD [18–20], are likely to differ across countries and change with time. An important
additional consideration in access to and uptake of RRT remains ethnic/racial background.
Some racial groups such as Black Americans and Asians have both an increased risk of
type 2 diabetes and an increased risk of progression to CKD and ESKD than Whites, but
are less likely to receive RRT [21–23]. The burden of ERSD is also higher in Aboriginal than
White Australians [24], but a recent national database study acknowledged that registration
of more severe cases might lead to an overestimation of rates of RRT complicating type
2 diabetes in Aboriginal Australians [14].
We have previously shown that CVD outcomes in well-characterized Australians with
type 2 diabetes from the Fremantle Diabetes Study Phases I (FDS1; recruited 1993–1996) and
II (FDS2; recruited 2008–2011) improved significantly between phases and proportionately
more than in matched people without diabetes from the same geographic area [1]. The
aims of the present study were (i) to determine whether changes in five-year incidence
rates (IRs) of RRT paralleled those of CVD outcomes in the 15 years separating the two FDS
phases, (ii) to compare these RRT IRs with those from matched people without known
diabetes from the same geographical area, and (iii) to examine the independent predictors
of RRT within the pooled FDS type 2 diabetes cohorts including the influence of FDS phase.
We also analyzed our data according to whether or not participants were Aboriginal to
quantify the relative burden of RRT in these participant groups.
2. Patients and Methods
2.1. Study Site, Participants, and Approvals
The FDS1 is an observational, longitudinal study of known diabetes conducted in
a postcode-defined geographic area surrounding the port city of Fremantle in the Australian
state of Western Australia (WA) [25]. Recruitment took place between 1993 and 1996, with
follow-up for initiation of RRT in the present sub-study to end-2017. The FDS2 utilized the
same design as FDS1 with recruitment between 2008 and 2011 and, in the case of the present
study, follow-up to end-2016. Socio-economic data from the study catchment area at the
time of FDS2 recruitment showed an average Index of Relative Socio-economic Advantage
and Disadvantage [26] of 1033, with a range across the included postcodes of 977–1113.
These figures parallel the Australian national mean ± SD (1000 ± 100), confirming that
FDS participants were from a representative urban Australian community.
Participants in both FDS phases were identified from hospital, clinic, and primary care
patient lists, advertising through local print media, pharmacies, optometrists, networks of
health care professionals, and, in the case of FDS2, third-party mail-outs to registrants of
the Australian National Diabetes Services Scheme and the National Diabetes Register [25].
Details of recruitment, sample characteristics including classification of diabetes types, and
non-recruited patients have been published previously [25,27]. The FDS1 protocol was
approved by the Fremantle Hospital Human Rights Committee in February 1993, and the
FDS2 protocol by the Human Research Ethics Committee of the Southern Metropolitan Area
Health Service in October 2007 (07/397). All participants gave written informed consent.
In FDS1, 2258 people with diabetes were identified from a population of approximately 120,000, and 1426 (63%) were recruited, of whom 1296 (91%) had clinically defined
type 2 diabetes. In FDS2, 4639 people with diabetes were identified from a population of
approximately 157,000, and 1668 (36%) were recruited, of whom 1509 (90%) had type 2 diabetes. Four age-, sex- and postcode-matched residents without any prior documentation
of diabetes in health databases were randomly selected from the study catchment area for
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each FDS1 and FDS2 participant at the time of their enrolment using the WA Electoral Roll
of all adults resident in the FDS catchment area and, for FDS2, the WA Registry for Births,
Deaths and Marriages. Five of these residents died just before their matched participant
with diabetes was enrolled in FDS1 and were therefore excluded. Matches could not be
made for five young and four elderly FDS1 participants who were also excluded. This left
1291 FDS1 participants with type 2 diabetes (99.6%) who were matched with 5159 residents
without diabetes. In the case of FDS2, the 1509 participants with type 2 diabetes were age-,
sex-, and postcode-matched with 6036 residents without diabetes.
2.2. Baseline and Annual Assessments
In both FDS phases, assessment at entry and at each annual (FDS1) or biennial (FDS2)
review included a comprehensive questionnaire, physical examination, and fasting biochemical tests performed in a single nationally accredited laboratory [25]. Demographic,
socio-economic, and lifestyle data were recorded in addition to details of all medical
conditions. Ethnic background was based on self-selection, country/countries of birth
and parents’ birth and, (in FDS2) country of grandparents’ birth, as well as language(s)
spoken at home. Six categories were used, specifically, Anglo-Celt, Southern European,
Other European, Asian, Aboriginal Australian, or Mixed/other [25]. Consistent with
Australian legal rulings and other studies of Aboriginal Australians with diabetes, we
used self-identification and acceptance by the local community as primary criteria for
Aboriginality [28]. There were no FDS participants who identified themselves as from
a Torres Strait Islander racial background. Patients were requested to bring all prescribed,
over-the-counter, and complementary medications to each visit and full details of these
were recorded. In FDS2, comprehensive postal questionnaires were sent to participants in
the alternate years between face-to-face assessments.
Complications were identified under standard definitions [29]. Albuminuria was
assessed from early morning spot urine albumin–creatinine ratio (ACR) measurement and
renal impairment from the estimated glomerular filtration rate (eGFR) [30]. Peripheral
sensory neuropathy (PSN) was ascertained using the clinical portion of the Michigan Neuropathy Screening Instrument [31]. Retinopathy was defined as one microaneurysm in
either eye or worse and/or evidence of laser treatment on direct/indirect ophthalmoscopy
(FDS1) or fundus photography (FDS2), and/or external assessment by an ophthalmologist.
Patients classified as having prevalent coronary heart disease (CHD) had history of MI,
angina, coronary artery bypass grafting, or angioplasty, and those with prevalent cerebrovascular disease had a history of stroke and/or transient ischemic attack. Peripheral
arterial disease (PAD) was defined as an ankle brachial index ≤0.90 or a diabetes-related
lower extremity amputation.
2.3. Ascertainment of Incident Renal Replacement Therapy
Outcomes of interest during follow-up were the first hospital admission for/with
RRT, death or five years, whichever came first. The Hospital Morbidity Data Collection
(HMDC) documents all public/private hospitalizations in WA since 1970, while the Death
Register contains information on all deaths in the state [32]. Both FDS phases have been
linked confidentially to these databases through the WA Data Linkage System (WADLS),
as approved by the WA Department of Health Human Research Ethics Committee. This
source provided validated data on incident events to end-2017 for FDS1 and end-2016 for
FDS2. Relevant International Classification of Disease (ICD)-9-CM and ICD-10-AM codes
were used to identify RRT in the HMDC. These comprised diagnosis codes V45.1, V56 and
996.81 (ICD-9-CM) and Z49, Z94.0, Z99.2 and T86.1 (ICD-10-AM), and procedure codes
55.69 (ICD-9-CM) and 36503-00 and 36503-01 (ICD-10-AM).
The HMDC was used as a source of additional data to those obtained through individual FDS assessments relating to prevalent/prior disease during the five years prior
to study entry, as well as providing the same information for matched residents without
diabetes. The final dataset was used to calculate the Charlson Comorbidity Index (CCI) [33]

J. Clin. Med. 2022, 11, 695

4 of 15

which includes a history of (MI), heart failure (HF), PAD, cerebrovascular disease, chronic
pulmonary disease, rheumatic disease, peptic ulcer disease, hemiparesis or paraparesis,
renal disease, liver disease, and cancer. For the purposes of the present study, we excluded
those conditions coded as diabetes-specific complications (ICD-9-CM 250 and ICD-10-AM
E10-14 codes) in FDS participants.
2.4. Statistical Analysis
The computer packages IBM SPSS Statistics 25 (IBM Corporation, Armonk, NY, USA)
and StataSE 15 (College Station, TX, USA: StataCorp LP) were used for statistical analysis.
Data are presented as proportions, mean ± SD, geometric mean (SD range), or, in the case of
variables which did not conform to a normal or log-normal distribution, median and interquartile range (IQR). Two-sample comparisons were by Fisher’s exact test for proportions,
Student’s t-test for normally distributed variables, and Mann–Whitney U-test for other
variables. Five-year IRs for RRT were derived for each of the four groups defined by type
2 diabetes status and FDS Phase. Incident rate ratios (IRRs) for RRT were then calculated
for (i) those with type 2 diabetes in FDS2 versus FDS1, (ii) those without diabetes in FDS2
versus FDS1, and (iii) for those with type 2 diabetes versus no diabetes in FDS1 and FDS2
separately, with incident rate differences (IRDs) also calculated. To allow for differences in
age, sex, comorbidities, and management changes between phases, we adjusted for (i) age
as the timeline in a Cox model of time to first event for each outcome using people without
diabetes in FDS2 as reference, and (ii) in addition, sex, CCI and time between recruitment
of each participant and recruitment of the first participant in each phase.
For the pooled FDS1 and FDS2 type 2 diabetes cohort, Cox proportional hazards
modeling with backward conditional variable entry (p < 0.05) and removal (p ≥ 0.05) were
used to determine independent predictors of the first episode of RRT during follow-up
from clinically plausible baseline variables with p < 0.20 in bivariable analyses. To assess
the effect of FDS phase, participation in FDS2 versus FDS1 was then added to each most
parsimonious model. Missing values were multiply imputed (×20; see Supplementary
Table S1), defining imputation models that included each outcome.
3. Results
3.1. Participant Characteristics
The total sample of FDS1 and FDS2 participants combined with the two matched
cohorts without diabetes (n = 13,995) had a mean ± SD age of 64.8 ± 11.5 years, and 50.4%
were males. The baseline characteristics of the four cohorts are summarized in Table 1.
Thirty-one (0.2%) participants had chronic renal failure requiring hospitalization for/with
RRT at study entry and were therefore excluded from analyses of incident disease. The
FDS2 type 2 diabetes cohort had the largest baseline RRT prevalence (0.8%), which was
significantly higher than for the cohorts without diabetes (FDS2 0.1% and FDS1 0.2%), but
not the FDS1 type 2 after Bonferroni correction for multiple comparisons.
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Table 1. Characteristics at study entry of type 2 diabetes FDS1 and FDS2 participants and their
matched cohorts.

Number (%)
Age at FDS entry (years)
Sex (% male)
Aboriginal Australian (%)
History of hospitalization for/with RRT a (%)
Charlson Comorbidity Index b (%)
0
1–2
≥3

FDS1 Type 2
Diabetes

FDS1 No
Diabetes

FDS2 Type 2
Diabetes

FDS2 No
Diabetes

1291
64.0 ± 11.2
48.7
1.5
0.2

5159
64.0 ± 11.2
48.7
0.2
***
85.6
11.1
3.3

1509
65.4 ± 11.7 **,†††
51.8
7.1
0.8 ††
**,†††
75.1
16.8
8.0

6036
65.4 ± 11.7 ***,†††
51.8 ††
0.1 ‡‡‡
***,‡‡‡
86.5
9.8
3.7

71.6
22.0
6.4

p-Value

<0.001
0.005
<0.001
<0.001

a

RRT = renal replacement therapy; b in the last 5 years, excluding diabetes and its complications; ** p < 0.01, ***
p < 0.001 vs. FDS1 type 2 diabetes; †† p < 0.01, ††† p < 0.001 vs. FDS1 no diabetes; ‡‡‡ p < 0.001 vs. FDS2 type
2 diabetes, Bonferroni-corrected for multiple comparisons.

3.2. Incident RRT by Type 2 Diabetes Status and FDS Phase
For the type 2 diabetes cohorts, the 5-year IR for RRT was nearly threefold higher
in FDS2 compared with FDS1 (IRR (95% CI): 2.85 (1.01–9.87); see Table 2 and Figure 1).
Sixteen more people per 10,000 person-years received RRT in FDS2 than FDS1. For the
two cohorts without diabetes matched to participants in FDS1 and FDS2, the 5-year IR
for RRT was sixfold higher in FDS2 than FDS1 (see Table 2 and Figure 1), but the IRR
had a wide confidence interval which spanned unity due to the low number of events.
Two more people per 10,000 person-years received RRT in the FDS2 cohort without diabetes
than the FDS1 cohort without diabetes.
Table 2. Five-year incidence rates (IR; per 10,000 person-years), incidence rate ratios (IRR; 95% CI)
and incident rate differences (IRD; per 10,000 person-years) for first hospitalization for/with renal
replacement therapy in FDS2 versus FDS1 type 2 diabetes participants and their matched counterparts
without diabetes for the total sample (above) and non-Aboriginal participants (below).
FDS1
Type 2
Diabetes

N

FDS2

Follow-Up
(Years)

Total
sample
Yes
≤5 *
5956
No
≤5 *
24,376
Non-Aboriginal participants
Yes
≤5 *
5872
No
≤5 *
24,009

FDS2:FDS1

FDS2—FDS1

IR

N

Follow-Up
(Years)

IR

IRR (95% CI)

IRD (95% CI)

8.40 (2.73–19.6)
0.41 (0.01–2.29)

17
7

7115
28,540

23.9 (13.9–38.3)
2.45 (0.99–5.05)

2.85 (1.01–9.87)
5.98 (0.77–269)

15.5 (1.97–29.0)
2.04 (0.06–4.03)

8.52 (2.76–19.9)
0.42 (0.01–2.32)

9
7

6636
26,467

13.6 (6.20–25.7)
2.64 (1.06–5.45)

1.59 (0.48–6.05)
6.35 (0.82–286)

5.05 (−6.54–16.6)
2.23 (0.11–4.35)

* Actual numbers not given to preserve confidentiality.

Excluding participants with an Aboriginal background and their matched counterparts
in FDS1, ≤5 (≤0.4%) of the 1271 non-Aboriginal participants with type 2 diabetes started
RRT in the five years following study entry compared with ≤5 (≤0.01%) of 5075 in the
corresponding matched cohort. The respective figures for FDS2 were 9 (0.6%) of the
1397 non-Aboriginal participants with type 2 diabetes versus 7 (0.1%) of the 5603 in the
matched cohort. For the type 2 diabetes cohorts excluding Aboriginal participants, the
5-year IR for RRT was a non-significant 59% higher in FDS2 compared with FDS1 (IRR
(95% CI): 1.59 (0.48–6.05); see Table 2 and Figure 1).
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Figure 1. Incidence rate ratios (IRRs) and incidence rate differences (IRDs) for renal replacement
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3.3. Determinants of Incident Renal Replacement Therapy
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in
the
for the competing risk of death (see Table 4).
context
low
numbers. Further
for sex, CCI,
and timeby
from
start
the
Theofage
ofevent
first occurrence
of RRT adjustment
showed no significant
difference
phase
orof
type
phase modestly
attenuated
these findings,
allowing
for thestudy
competing
2respective
diabetes status,
but the oldest
age of starting
RRT inas
thedid
5 years
following
entry
risk 69.9
of death
was
years(see
for Table
FDS1 4).
and more than 15 years greater at 85.4 years for FDS2. Excluding
the eight participants with an Aboriginal background and their matched counterparts
increased the mean age of RRT onset for those with type 2 diabetes in FDS2 from 61.6 years
(range 33.2–85.4 years) to 74.5 years (range 63.2–85.4 years).
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Table 4. Cox and Fine and Gray models, and age at first hospitalization for/with renal replacement
therapy (RRT), occurring within 5-years of study entry by FDS Phase and type 2 diabetes status in
those with no prior hospitalization for/with RRT.
Phase

Type 2
Diabetes

N

Events

CsHR a
(95% CI)

CsHR b
(95% CI)

SdHR a
(95% CI)

SdHR b
(95% CI)

Age at Event
(Years)

6027
1497
5151
1289

7
17
≤5 *
≤5 *

1.0
10.1 (4.20, 24.5)
0.16 (0.02, 1.28)
3.17 (1.01, 10.0)

1.0
7.17 (2.90, 17.7)
0.16 (0.02, 1.32)
2.22 (0.69, 7.27)

1.0
9.89 (4.08, 24.0)
0.15 (0.02, 1.24)
2.97 (0.95, 9.33)

1.0
7.25 (2.88, 18.2)
0.15 (0.02, 1.26)
2.11 (0.58, 7.65)

67.9 ± 7.6
61.6 ± 16.0
49.4
62.9 ± 8.9

Total sample
2
2
1
1

No
Yes
No
Yes
Non-Aboriginal
participants

2

No

5603

7

1.0

1.0

1.0

1.0

9
≤5 *
≤5 *

5.12 (1.91, 13.8)

3.69 (1.35, 10.1)

5.03 (1.88, 13.5)

3.86 (1.44, 10.4)

0.15 (0.02, 1.22)

0.14 (0.02, 1.17)

0.14 (0.02, 1.15)

0.13 (0.02, 1.11)

3.06 (0.97, 9.67)

1.96 (0.60, 6.37)

2.86 (0.92, 8.89)

1.86 (0.53, 6.53)

2

Yes

1397

1

No

5075

1

Yes

1271

67.9 ± 7.6
(55–75)
74.5 ± 6.4
(63–85)
49.4
62.9 ± 8.9
(48–69)

Cs = cause-specific; sd = subdistribution; HR = hazard ratio; CI = confidence interval; * actual numbers not given to
preserve confidentiality; a adjusted for age as timeline; b adjusted for age as timeline, sex, Charlson’s Comorbidity
Index, time from recruitment of first participant in each Phase to study entry for each participant/matched.

3.4. Predictors of Outcomes in Pooled FDS1 and FDS2 Type 2 Diabetes Datasets
At study entry, the pooled FDS1 and FDS2 participants with type 2 diabetes (n = 2805)
had a mean ± SD age of 64.8 ± 11.5 years; 50.3% were male, and their median (IQR)
diabetes duration was 5.0 (1.8–13.0) years. The baseline characteristics of the FDS1 and
FDS2 type 2 diabetes cohorts are summarized in Table 5. Compared with the FDS1 cohort,
those in FDS2 were older at entry, had greater ethnic heterogeneity, were more fluent in
English, and were better educated. They consumed more alcohol but were less likely to
be current smokers. They were diagnosed at a younger age and had a longer diabetes
duration, their diabetes was more intensively managed pharmacologically, and they had
better glycemic control if more self-reported hypoglycemia. The FDS2 participants were
more likely to be obese, but had lower systolic blood pressure and more favorable serum
lipid levels in association more intensive CVD risk factor pharmacotherapy including use
of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. They had
lower urinary ACRs and higher eGFRs. More had a past history of stroke, PSN, and RRT,
but fewer had PAD and depressive symptoms.
Table 5. Comparison of the characteristics of type 2 diabetes participants in FDS1 and FDS2 at study entry.
p-Value

FDS1

FDS2

Number (%)

1296 (46.2)

1509 (53.8)

Time from start of Phase to participant entry (years)

1.21 ± 0.83

1.59 ± 0.93

<0.001

Age at FDS entry (years)

64.0 ± 11.3

65.4 ± 11.7

0.001

Sex (% male)

48.6

51.8

0.10

Overseas born (%)

46.8

43.5

0.09

Ethnic background (%):
Anglo-Celt

61.4

52.6

Southern European

17.7

12.9

Other European

8.5

7.4

Asian

3.4

4.3

<0.001
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Table 5. Cont.
FDS1

FDS2

Aboriginal Australian

1.5

7.1

Mixed/other

7.5

15.8

p-Value

Not fluent in English (%)

15.3

10.8

<0.001

Education beyond primary level (%)

74.0

86.8

<0.001

Currently married/de facto (%)

65.7

62.7

0.11

Alcohol (standard drinks/day)

0 (0–0.8)

0.1 (0–1.2)

<0.001

Smoking status (%)
Never

44.7

45.5

Ex-

40.2

43.9

Current

15.1

10.7

Age at diagnosis (years)

57.9 ± 11.7

55.6 ± 12.4

<0.001

Duration of diabetes (years)

4.0 (1.0–9.0)

8.0 (2.7–15.4)

<0.001

Diabetes treatment (%):
Diet

31.9

24.6

Oral agents

55.7

53.4

Insulin ± oral agents

12.3

22.0

Fasting serum glucose (mmol/L)

8.0 (6.5–10.3)

7.2 (6.2–8.9)

<0.001

HbA1c (%)

7.2 (6.2–8.5)

6.8 (6.2–7.7)

<0.001

HbA1c (mmol/mol)

55 (44–69)

51 (44–61)

<0.001

Self-reported hypoglycemia last year (%):

22.9

33.9

<0.001

29.6 ± 5.4

31.3 ± 6.1

<0.001

Obesity (% by waist circumference)

64.5

70.9

<0.001

Antihypertensive medication (%)

50.9

73.2

<0.001

Angiotensin converting enzyme
inhibitors/angiotensin receptor antagonists (%)

21.8

64.5

<0.001

Systolic blood pressure (mm Hg)

151 ± 24

146 ± 22

<0.001

Diastolic blood pressure (mm Hg)

80 ± 11

80 ± 12

0.55

Body mass index

(kg/m2 )

0.001

<0.001

Heart rate (/min)

70 ± 12

70 ± 12

0.85

Lipid-modifying medication (%)

10.5

68.2

<0.001

Total serum cholesterol (mmol/L)

5.5 ± 1.1

4.4 ± 1.1

<0.001

Serum HDL-cholesterol (mmol/L)

1.06 ± 0.33

1.24 ± 0.34

<0.001

Serum triglycerides (mmol/L)

2.2 (1.2–3.9)

1.5 (0.9–2.5)

<0.001

Serum uric acid (mmol/L)

0.38 ± 0.11

0.34 ± 0.09

<0.001

Aspirin use (%)

22.0

37.2

<0.001

Urinary albumin:creatinine (mg/mmol)

5.2 (1.5–17.8)

3.3 (0.8–12.7)

<0.001

eGFR categories (%):
≥90 mL/min/1.73 m2

32.2

38.9

60–89 mL/min/1.73 m2

49.8

44.6

45–59 mL/min/1.73

m2

11.9

8.8

30–44 mL/min/1.73

m2

4.4

4.9

1.7

2.8

<30 mL/min/1.73

m2

<0.001
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Table 5. Cont.
FDS1

FDS2

p-Value

Hospitalization for/with RRT (%)

0.2

0.8

0.016

Atrial fibrillation (%)

4.9

4.6

0.72

Hospitalization for/with heart failure (%)

8.3

6.4

0.07

Hospitalization for/with myocardial infarction (%)

8.7

8.1

0.59

Ischemic heart disease (%)

29.6

28.8

0.68

Hospitalization for/with stroke (%)

0.4

3.0

<0.001

Cerebrovascular disease (%)

10.0

11.2

0.30

Hospitalization for lower extremity amputation (%)

1.2

1.1

0.86

Peripheral arterial disease (%)

29.3

22.6

<0.001

Peripheral sensory neuropathy (%)

30.8

58.2

<0.001

Depressive symptoms (%)

31.5

23.1

<0.001

ApoE genotype (%):
22

0.8

0.4

23

11.8

11.4

24

2.3

2.5

33

65.5

64.5

34

18.3

19.4

44

1.2

1.8

ApoE4 allele (%)

21.9

23.7

Charlson Comorbidity Index a (%):

a

0.54

0.27
0.001

0

71.5

75.1

1–2

22.1

16.8

≥3

6.4

8.0

In the last 5 years, excluding diabetes and its complications.

Excluding those with prior RRT, the baseline characteristics of the pooled cohort by
incident RRT status are summarized in Supplementary Table S2. The most parsimonious
Cox models of time to RRT, which utilized age as the time scale and incorporated imputation
of missing data (see Supplemental Table S1), are shown in Table 6. The predictors of
RRT were consistent with recognized risk factors, including urinary ACR, baseline renal
impairment, and Aboriginal Australian background. Addition of FDS Phase to the most
parsimonious models showed participation in FDS2 versus FDS1 was associated with
a non-significant threefold increase in risk of RRT.
After excluding participants with an Aboriginal ethnic background, the only predictors
of RRT were urinary ACR and baseline renal impairment (see Table 6). Addition of FDS
Phase to the most parsimonious model showed that participation in FDS2 versus FDS1 was
associated with a non-significant doubling of the risk of RRT.
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Table 6. Multiply imputed Cox models of time to first hospitalization for/with RRT, with age as
time scale in pooled FDS1 and FDS2 participants with type 2 diabetes (HR (95% CI)). Model 1: Most
parsimonious model; Model 2: Model 1 with FDS2 added.

Total sample
n/N
Aboriginal
Ln(ACR (mg/mmol)) *
eGFR (CKD-EPI):
45–59 mL/min/1.73 m2
30–44 mL/min/1.73 m2
<30 mL/min/1.73 m2
FDS2
Non-Aboriginal participants
n/N
Ln(ACR (mg/mmol)) *
eGFR (CKD-EPI) <30 mL/min/1.73 m2
FDS2

Model 1

Model 2

22/2787
6.41 (1.02–40.1)
2.52 (1.77–3.58)

22/2787
3.84 (0.56–26.3)
2.57 (1.81–3.65)

22.4 (2.34–214)
39.3 (4.03–383)
221 (23.4–2081)

22.1 (2.38–205)
47.1 (4.59–482)
230 (26.1–2036)
3.13 (0.81–12.1)

14/2673
2.78 (1.84–4.20)
22.8 (5.91–87.8)

14/2673
2.78 (1.85–4.17)
24.5 (6.42–93.2)
2.22 (0.59–8.35)

* An increase of 1 in ln(ACR (mg/mmol)) equates to an increase of 2.72 in ACR (mg/mmol).

4. Discussion
The present data show that the incidence of RRT tripled in the 15 years between FDS
Phases in people with type 2 diabetes from a representative urban Australian setting. The
observation that the IRR was attenuated when Aboriginal participants were excluded
from the analysis suggests that rates of RRT have been increasing disproportionately in
Aboriginal Australians with type 2 diabetes. Although constrained by a relatively small
numbers of events, there was also a non-significant temporal trend to increasing incidence
of RRT among matched people without diabetes from the same catchment area. Type
2 diabetes increased the risk of RRT at least 5-fold compared to that in people without
diabetes. This increased risk was much greater in the Aboriginal participants, and there
was evidence that this group was relatively young at the time RRT was started and that they
were more prone to rapid progression to RRT. Multivariable analysis using the combined
FDS cohorts confirmed albuminuria as a strong independent risk factor for RRT.
The temporal increase in RRT in type 2 diabetes in the present study is in apparent
contrast to the significant reduction in major cardiovascular events found in a similar
analysis of FDS2 compared with FDS1 [1]. Nevertheless, an Australian national database
study conducted over a shorter time period than FDS (between 2002 and 2013) also found
an increasing incidence of ESKD in type 2 diabetes [14], with an overall crude incidence rate
similar to that in FDS1 (9.1 versus 8.4/10,000 person-years). The substantial increase in RRT
in FDS2 (to 23.9/10,000 person-years) might represent the effect of an additional 3 years of
follow-up in FDS2 coupled with progressively greater willingness to treat diabetes-related
ESKD in Australia [34]. In addition, 7.1% of FDS2 participants were Aboriginal compared
with only 1.5% in FDS1 and 2.1% in the national sample, the latter having acknowledged
deficiencies in Aboriginal registrations [14]. Notwithstanding these differences, the national
database study found that Aboriginal ESKD rates were four times those in non-Aboriginal
registrants [14], a figure similar to the hazards ratios in our Cox proportional hazards models.
There is evidence that improved CVD risk factor management has contributed to
reduced macrovascular complications of type 2 diabetes over the past few decades [7–9],
including in the context of diabetic kidney disease [35]. Better cardiometabolic control, if
appropriately implemented across all levels of care [36], might also be expected to slow
progression to ESKD [37]. However, increased survival from major CVD events might
also increase the number of people with type 2 diabetes requiring RRT. It is of interest
that adjusting for the competing risk of premature death did not attenuate the HRs in the
present analyses. Although the age at which RRT was started was similar for people with
type 2 diabetes in FDS1 and FDS2 (at around 62 years), the SD for this variable in FDS2
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was approaching twice that in FDS1 (16 years versus 9 years), suggesting a much broader
age spread in the later phase of the FDS. This might mean that, as well as people with
type 2 diabetes in FDS2 living longer and being more readily accepted into RRT programs
than in FDS1 [34], there are also increasing numbers of younger individuals requiring RRT.
The greater age at RRT initiation in non-Aboriginal FDS2 participants with type 2 diabetes
(75 years) suggests strongly that Aboriginals with type 2 diabetes are progressing to ESKD
at a relatively young age, in accord with previous studies [38]. Consistent with our data, the
national database study found that the increasing annual incidence of ESKD was driven by
increases among those younger than 50 and older than 80 years [14]. We [39] and others [40]
have found that type 2 diabetes in young people is associated with a more severe phenotype
and relatively high rates of chronic complications which likely include ESKD.
As well as confirmation of albuminuria as a strong predictive risk factor for ESKD [41],
there was indirect evidence from our comparative Cox models that Aboriginals can progress
more rapidly from Stage 3 CKD to requiring RRT. In the total sample of FDS1 and FDS2
participants with type 2 diabetes, there was a graded relationship between the baseline
eGFR and incident RRT from a HR of 22.4 in those with an eGFR at study entry between
45 and 59 mL/min/1.73 m2 to one of 221 for those with an eGFR < 30 mL/min/1.73 m2
(Table 6). When the same analysis was repeated in the non-Aboriginal participants, only
those with an eGFR < 30 mL/min/1.73 m2 were at increased risk (HR 22.8). Consistent
with this observation, Aboriginal participants in both FDS phases had worse baseline renal
disease risk factor profiles, including a higher HbA1c and a greater proportion of smokers,
than their non-Aboriginal counterparts [28].
The present study had limitations. Although the FDS2 cohort was from a typical
urban Australian population base and was representative of those with the disease in the
study catchment area, the number of RRT endpoints was relatively small and a function
of the fixed sample sizes. Nevertheless, the incident rates for RRT and their trends were
similar to those in the national sample [14], and the non-significant increasing incidence
of RRT among matched people without diabetes was consistent with upward trends in
RRT for other causes of ESKD in the Australian general population [34]. Although we
had robust identification of Aboriginality in the FDS cohorts, this was not the case for the
matched cases without diabetes from the catchment area and so we assumed that those
matched with the Aboriginals in the FDS T2D cohorts were also Aboriginal. Given that
the average age of Aboriginals in Australia is 20 years compared with 38 years in the
non-Aboriginal population [42], it is likely that the groups of individuals without diabetes
matched with the relatively young Aboriginals in FDS1 and FDS2 were enriched with
Aboriginals. The uptake of the glucagon-like peptide 1 receptor agonists and sodiumglucose co-transporter-2 inhibitors (SGLT2i), classes of blood glucose-lowering therapies
with glucose-independent benefits for renal disease, especially SGLT2i [43], was relatively
low in the FDS2 cohort (<5% in each case at the end of the follow-up period) given that they
were first introduced into Australia when the study was in progress. In any case, any effect
they may have had on the incidence of RRT would have been an attenuation of the increase
between FDS1 and FDS2. The strengths of the study include the detailed participant-level
data and access to a validated data linkage system with ascertainment of relatively hard
renal-related endpoints.
In conclusion, the present study provides patient-level evidence from a representative
urban community sample that the incidence of RRT in type 2 diabetes has increased over
the last few decades. This finding aligns with recent national Australian administrative
data [14], but we provide additional evidence of the increased risk of ESKD amongst
Aboriginal people with type 2 diabetes who can present at a young age and can progress
rapidly to RRT in the presence of relatively adverse renal risk factors. The increasing
incidence of RRT in type 2 diabetes may be multifactorial, but increased willingness to
implement this management strategy in older individuals with comorbidities [34] as well
as a more severe clinical phenotype in younger, especially Aboriginal patients, appear
largely responsible.
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